[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse NLN

Summary
SymbolNLN
Nameneurolysin (metallopeptidase M3 family)
Aliases KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location5q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion intermembrane space Cytoplasm
Domain PF01432 Peptidase family M3
Function

Hydrolyzes oligopeptides such as neurotensin, bradykinin and dynorphin A.

> Gene Ontology
 
Biological Process GO:0005996 monosaccharide metabolic process
GO:0006006 glucose metabolic process
GO:0006094 gluconeogenesis
GO:0006109 regulation of carbohydrate metabolic process
GO:0006111 regulation of gluconeogenesis
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0010675 regulation of cellular carbohydrate metabolic process
GO:0010830 regulation of myotube differentiation
GO:0010906 regulation of glucose metabolic process
GO:0014706 striated muscle tissue development
GO:0014902 myotube differentiation
GO:0016051 carbohydrate biosynthetic process
GO:0016202 regulation of striated muscle tissue development
GO:0019318 hexose metabolic process
GO:0019319 hexose biosynthetic process
GO:0035914 skeletal muscle cell differentiation
GO:0042692 muscle cell differentiation
GO:0043255 regulation of carbohydrate biosynthetic process
GO:0044262 cellular carbohydrate metabolic process
GO:0044283 small molecule biosynthetic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0046364 monosaccharide biosynthetic process
GO:0048634 regulation of muscle organ development
GO:0048641 regulation of skeletal muscle tissue development
GO:0051146 striated muscle cell differentiation
GO:0051147 regulation of muscle cell differentiation
GO:0051153 regulation of striated muscle cell differentiation
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0098528 skeletal muscle fiber differentiation
GO:1901861 regulation of muscle tissue development
GO:1902809 regulation of skeletal muscle fiber differentiation
GO:2001014 regulation of skeletal muscle cell differentiation
Molecular Function GO:0004175 endopeptidase activity
GO:0004222 metalloendopeptidase activity
GO:0008237 metallopeptidase activity
GO:0033218 amide binding
GO:0042277 peptide binding
Cellular Component GO:0005758 mitochondrial intermembrane space
GO:0031970 organelle envelope lumen
> KEGG and Reactome Pathway
 
KEGG hsa04614 Renin-angiotensin system
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-500792: GPCR ligand binding
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolNLN
Nameneurolysin (metallopeptidase M3 family)
Aliases KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location5q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NLN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNLN
Nameneurolysin (metallopeptidase M3 family)
Aliases KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location5q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NLN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -1.05; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolNLN
Nameneurolysin (metallopeptidase M3 family)
Aliases KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location5q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NLN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1120.696
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2160.845
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0410.964
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1830.49
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1910.9
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1720.929
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0110.976
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2310.883
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2220.903
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.5380.612
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2060.882
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0230.828
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NLN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNLN
Nameneurolysin (metallopeptidase M3 family)
Aliases KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location5q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NLN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNLN
Nameneurolysin (metallopeptidase M3 family)
Aliases KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location5q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NLN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NLN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNLN
Nameneurolysin (metallopeptidase M3 family)
Aliases KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location5q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NLN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNLN
Nameneurolysin (metallopeptidase M3 family)
Aliases KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location5q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NLN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNLN
Nameneurolysin (metallopeptidase M3 family)
Aliases KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location5q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NLN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNLN
Nameneurolysin (metallopeptidase M3 family)
Aliases KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location5q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NLN collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.